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Abstract 56 
BRCA1/2 germline mutations predispose to breast cancer (gBRCA-BC) by impairing homologous 57 
recombination (HR) causing genomic instability. HR also repairs DNA lesions caused by platinums and PARP 58 
inhibitors. Triple Negative Breast Cancers (TNBC) harbour sub-populations with BRCA1/2 mutations, 59 
hypothesised to be especially platinum sensitive. Putative “BRCAness” subgroups may also be especially 60 
platinum sensitive. We assessed carboplatin and mechanistically distinct docetaxel in a phase-III trial in 61 
unselected advanced TNBC. A pre-specified programme enabled biomarker-treatment interaction analyses in 62 
gBRCA-BC and “BRCAness” subgroups: tumour BRCA1 methylation; BRCA1 mRNA-low; HR deficiency 63 
mutational signatures and basal phenotypes. Primary endpoint was objective response rate (ORR) . In the 64 
unselected population (376 patients; 188 carboplatin, 188 docetaxel) carboplatin was not more active than 65 
docetaxel (ORR: 31.4v34.0; p=0.66). In contrast in patients with gBRCA-BC carboplatin had double the ORR 66 
compared to docetaxel (68%v33%), test for biomarker-treatment interaction (p=0.01). No treatment interaction 67 
was observed for BRCA1 methylation, BRCA1 mRNA-low status or a Myriad-HRD mutation signature assay. 68 
Significant treatment interaction with basal-like subtype was driven by high docetaxel response in the non-basal 69 
subgroup. Patients with advanced TNBC  benefit from BRCA1/2 mutation characterization, but not BRCA1 70 
methylation or Myriad-HRD analysis, informing platinum choices. Basal-like gene expression analysis may also 71 
influence treatment choices.72 
Introduction  73 
“Triple negative” breast cancer (TNBC) describes the 10-20% of tumours which are estrogen receptor (ER), 74 
progesterone receptor (PgR) and HER2 negative. A single TNBC entity is however a fallacy masking 75 
considerable histological and biological heterogeneity, understanding of which is needed to optimise therapy 76 
selection. Outcome for patients with recurrent/advanced TNBC is especially poor1. Chemotherapy is the only 77 
approved systemic therapy and, while considered biologically unselective, can have distinct mechanisms of 78 
action that target specific biological mechanisms aberrant in cancer. When accompanied by mechanism relevant 79 
biomarkers, use of a specific chemotherapeutic in defined populations might be considered a “targeted” therapy.  80 
 81 
Whilst genomic classifiers suggest the majority of TNBCs are of basal intrinsic subtype2,3, recent analyses 82 
suggest that TNBC can be sub-classified4-6. An immunohistochemical (IHC) approximation of the basal intrinsic 83 
subtype has been termed “core basal”7. A common feature of sporadic basal TNBC is genomic instability with 84 
mutational and rearrangement signatures indicative of abnormalities in DNA repair and replication stress that 85 
overlap BRCA1 or BRCA2 mutation associated signatures8. Abnormalities also exist in BRCA1 mRNA 86 
expression, largely driven through methylation of the BRCA1 promoter 9,10 as observed in ovarian cancer11,12. 87 
This, and the overlap in mutational signatures8, suggest functional deficiency of homologous recombination 88 
(HR) DNA repair genes as a shared characteristic between BRCA1 familial breast cancers and a substantial, but 89 
incompletely defined, subgroup of TNBC. BRCA1 and BRCA2 proteins have important roles in DNA 90 
replication fork stabilisation and HR13 and are components of the Fanconi anaemia protein network14,15. The 91 
hallmark of deficiency in this network is sensitivity to DNA crosslinks induced by platinums and mitomycin 92 
C16,17. Historically platinum chemotherapies have only shown modest activity in advanced breast cancer 93 
excepting those with chemotherapy naïve disease18,19.  94 
 95 
No trial had directly studied platinum therapy responses in comparison to standard of care in advanced 96 
unselected TNBC, its majority basal subtype or subgroups of TNBC with features of aberrant BRCA1/2 97 
associated function or “BRCAness”20. TNT was designed to compare the activity of the standard of care 98 
microtubule agent docetaxel with the DNA cross-linking agent carboplatin. We hypothesised greater activity for 99 
carboplatin in DNA damage response deficient subgroups. As strong mechanistic evidence existed for the 100 
efficacy of platinum DNA salts on cells with BRCA1 or BRCA2 mutations, accrual of patients known to have 101 
these germline mutations was allowed, irrespective of ER, PgR and HER2 status. We pre-specified analyses of 102 
i) germline mutation carriers and putative “BRCAness”21 TNBC subgroups with ii) BRCA1 promoter DNA 103 
methylation and/or mRNA-low and basal forms of the TNBC defined by iii) gene or iv) protein expression. 104 
 105 
 106 
Results 107 
Between 25 April 2008 and 18 March 2014 376 patients (188 allocated to carboplatin and 188 to docetaxel) 108 
entered the trial, all patients were included in the analysis of the primary endpoint (Figure 1); the trial population 109 
largely comprised patients with TNBC and no known BRCA1/2 mutation (338/376) and baseline characteristics 110 
typical of patients with first line relapse of TNBC (Table S2/S3). There were 43 patients with germline 111 
BRCA1/2 mutation (31 BRCA1 and 12 BRCA2 Table S2). Of the 31 BRCA1 mutation carriers 4 had ER+ve  112 
disease and of the 12 BRCA2 mutation carriers 7 had ER+ve disease. Compliance with allocated treatment was 113 
good; disease progression and toxicity were the principal reasons for early discontinuation. Median relative dose 114 
intensity was 94·0% (IQR 84·2, 99·8) for carboplatin and 94·8% (IQR: 84·8, 100·0) for docetaxel.  115 
 116 
Overall results 117 
There was no evidence of a difference between carboplatin and docetaxel in objective response rate in the 118 
overall population (ORR: 59/188 (31·4%) vs. 64/188 (34·0%), absolute difference -2·6%, (95%CI: -12·1 to 119 
6·9), p=0·66; Figure 2A). Following central review of locally classified responses, response rates were 48/188 120 
(25·5%) carboplatin vs. 55/188 (29·3%) docetaxel, absolute difference (C-D) = -3·8 (95%CI: -12·8, 5·2); exact 121 
p=0·49, consistent with findings from the main analysis. Similarly, no evidence of a difference was observed for 122 
crossover treatments (Figure S1A) or when analysis was limited to those centrally confirmed as having triple 123 
negative tumours (see supplementary appendix).  124 
 125 
372 (98·9%) patients have had PFS events reported. Median PFS in patients allocated carboplatin was 3·1 126 
months (95%CI: 2·4, 4·2) and 4·4 months (95%CI: 4·1, 5·1) for those allocated docetaxel. No difference in 127 
restricted mean PFS was found (difference -0·30 months, p=0·40; Figure 3A).  128 
 129 
347 patients are reported to have died. Median OS was 12·8 months (95%CI: 10·6, 15·3) and 12·0 months 130 
(95%CI: 10·2, 13·0) for those allocated carboplatin and docetaxel respectively. Consistent with the PFS result, 131 
no evidence of a difference was found between treatment groups (difference -0·03 months, p=0·96; Figure 132 
S2A). 133 
 134 
BRCA subgroup analyses 135 
Protocol pre-specified subgroup analyses by BRCA1/2 mutation were conducted at the time of the main analysis. 136 
Patients with a deleterious BRCA1/2 germline mutation had a significantly better response to carboplatin than 137 
docetaxel (ORR: 17/25 (68·0%) vs. 6/18 (33·3%), absolute difference 34·7%, p=0·03), with no evidence of 138 
differential treatment activity in patients with no germline mutation (ORR: 36/128 (28·1%) vs. 50/145 (34·5%), 139 
absolute difference -6·4%, p=0·30), resulting in a statistically significant interaction (p=0·01, Figure 2B). This 140 
result remained significant (p=0·01) after adjustment for known prognostic factors (see supplementary appendix 141 
for details). PFS also favoured carboplatin for patients with a BRCA1/2 germline mutation (median PFS 6·8 142 
months vs. 4·4 months, difference in restricted mean PFS 2·6 months, interaction p=0·002; Figure 3B) but no 143 
difference was found in overall survival (Figure S2B), with interpretation confounded by the pre-planned 144 
crossover at progression (Figure S1B). Given the small numbers of BRCA2 versus BRCA1 germline mutation 145 
carriers randomised, comparative analyses of treatment effect for each gene and in the very small number of  ER 146 
+ve tumours compared to those that were TNBC were neither significant nor meaningful. 147 
Patients with tumour available for sequencing and a BRCA1/2 mutation detected in their tumour sample (see 148 
Table S4 for overlap of tumour detected mutation with germline BRCA1/2 mutation status) appeared to have 149 
better response to carboplatin than docetaxel (ORR: 12/18 (66·7%) vs. 5/14 (35·7%), absolute difference 150 
31·0%, p=0·15) whilst a treatment effect favouring docetaxel was suggested in patients with wildtype genotype 151 
in the tumour (ORR: 23/90 (25·6%) vs. 32/90 (35·6%), absolute difference -10·0%, p=0·20). Given very small 152 
patient numbers with tumour mutation data neither of these subgroup analyses attained statistical significance; 153 
however, given the effects were in opposite directions, the interaction was significant (p=0·03) (Figure 2C). 154 
This however did not hold for PFS or OS (p=0·12, p=0·70 respectively) (Figures 3C and S2C). Eight patients 155 
had a wildtype germline genotype but a BRCA mutation in their tumour which was therefore classed as a 156 
somatic mutation (Table S4); 2/4 had responses with carboplatin and 2/4 with docetaxel, but small numbers 157 
limit conclusive interpretation of these data.  158 
 159 
Counter to our pre-specified hypothesis, patients with BRCA1 methylation  did not have better response to 160 
carboplatin than docetaxel (ORR: 3/14 (21·4%) vs. 8/19 (42·1%), absolute difference -20·7%, p=0·28) with no 161 
evidence of an interaction observed (p=0·35, Figures 2D, 3D, S2D); with similar conclusions when germline 162 
BRCA1/2 mutated patients were excluded.  163 
 164 
Concordant with BRCA1 methylation status, tumours we defined as BRCA1 mRNA-low, with which 165 
methylation was partially associated (Supplementary Figure S3 and Table S5), did not have a better response to 166 
carboplatin than docetaxel (ORR: 4/14 (28·6%) vs. 11/17 (64·7%), absolute difference -36·1%, p=0·07) and 167 
evidence of an interaction was lacking (p=0·07, Figures 2E, 3E, S2E), again conclusions were not different 168 
when germline BRCA mutations were excluded. Furthermore, exploratory analyses examining any relationship 169 
between high response to carboplatin and the cut-point for BRCA1 methylation or BRCA1 mRNA1-low did not 170 
suggest any significant signal that supported our a priori hypotheses that they would be associated with greater 171 
response to carboplatin than a taxane (data not presented). 172 
 173 
Homologous Recombination Deficiency subgroup analyses 174 
In the initial trial design and first protocol we hypothesized that changes in the genome landscape which may 175 
arise as a consequence of defects in homologous recombination could provide an indicator of platinum salt 176 
sensitivity and should be examined for interaction with treatment effect in both treatment arms. A number of 177 
these assays have been reported8,22-25. Here we show the result using the combined Myriad HRD assay26 178 
performed on treatment naïve primary tissue. We find that the great majority of patients with either germline 179 
BRCA1/2 mutation or BRCA1 methylation have an high Dichotomized “HRD Score”  (Figure S4A, S4B)  but 180 
“HRD Score”  high patients, unlike germline BRCA1/2 mutation carriers, did not have better response to 181 
carboplatin than docetaxel (ORR: 13/34 (38.2%) vs. 19/47 (40.4%), absolute difference -2.2%, p=1.0) with no 182 
evidence of an interaction observed (p=0·75,  Figure 4A). Similar results were found when “HR Deficient” 183 
patients, a definition that grouped all BRCA1/2 mutated patients with those BRCA1/2 wild-type patients with 184 
high HRD score, were examined (Figure 4B). In addition no evidence of treatment specific predictive effect for 185 
PFS was found using either HRD definition (Figure S5A,B). Patients with High HRD score had a numerically 186 
greater response to both chemotherapy agents than those with low scores but this does not appear statistically 187 
significant. 188 
 189 
Basal subgroup analyses 190 
Given association between germline BRCA1 mutation and the development of basal-like breast cancers we 191 
sought to formally test the premise that all basal-like cancers share a BRCA1 loss of function phenotype with 192 
those with mutation by analysing a platinum treatment interaction in this broader basal-like TNBC group. We 193 
found no evidence that Prosigna – PAM50 basal tumours showed greater response to carboplatin compared 194 
with docetaxel (ORR: 27/83 (32·5%) vs. 27/87 (31·0%), absolute difference 1·5%, p=0·87). However, in 195 
patients with non-basal-like tumours response to docetaxel was significantly better than to carboplatin (ORR: 196 
13/18 (72·2%) vs. 3/18 (16·7%), absolute difference -55·5%, p=0·002), leading to a significant interaction test 197 
(p=0·003, Figure 5A) and a similar trend in crossover treatment response (Figure S6). The interaction between 198 
treatment and PAM50 subgroups remained significant after adjusting for gBRCA status in the multivariable 199 
logistic regression model (p=0·002) (Table S6) and when other known prognostic factors were subsequently 200 
included in the model. The interaction was also significant for PFS (p=0·04) (Figure 6A) but not OS (p=0·17) 201 
(Figure S7A). 202 
 203 
There was no evidence that “core basal” tumours defined by IHC had improved response to carboplatin 204 
compared with docetaxel (ORR: 23/67 (34·3%) vs. 19/65 (29·2%), absolute difference 5·1%, p=0·58). While 205 
there was a higher response rate to docetaxel compared with carboplatin in patients with non-basal 5 marker 206 
negative (5NP) tumours (ORR: 13/31 (41·9%) vs 5/26 (19·2%), absolute difference -22·7%, p=0·09), the 207 
difference did not reach statistical significance and the interaction test was non-significant p=0·06 (Figures 5B, 208 
6B, S7B).   209 
 210 
Safety 211 
Both carboplatin and docetaxel demonstrated toxicity consistent with their known safety profiles and Grade 3 212 
and 4 adverse events (AEs) were as anticipated for these well-known chemotherapy drugs (Tables S7 and S8). 213 
There were more grade 3/4 AEs with docetaxel than with carboplatin. 276 Serious Adverse Events (SAEs) were 214 
reported throughout the trial (102 carboplatin; 174 docetaxel). The spectrum of SAEs was as anticipated. Two 215 
SAEs were considered to be Suspected Unexpected Serious Adverse Reactions (1 carboplatin; 1 docetaxel). 216 
These were i) nausea, vomiting and headaches; ii) low magnesium. One death was considered possibly related 217 
to carboplatin treatment; this patient died from pulmonary embolism. As an haplo-insuffiency or dominant 218 
negative effect of heterozygous mutation might affect toxicity from HR targeting therapies such as platinum in 219 
mutation carriers we sought evidence of excess haematological toxicity as a signal but found none (Table S9). 220 
Although there was a small numerical difference in non-haematological toxicity this was not significant and 221 
small numbers preclude firm conclusions from these analyses. 222 
 223 
Discussion 224 
This phase III trial utilised two mechanistically distinct single agent chemotherapeutics in unselected advanced 225 
TNBC and in a priori specified biomarker defined sub-populations thought likely to have targetable defects in 226 
HR DNA repair. In the unselected TNBC patients no evidence of a superior response to carboplatin was 227 
observed when compared with a standard of care taxane, docetaxel. Carboplatin was better tolerated than 228 
docetaxel delivered at the full licensed dose. This trial demonstrates significant activity for both agents and the 229 
level of response seen for docetaxel is consistent with that seen previously in breast cancer27 and for carboplatin 230 
with that seen in uncontrolled trials of single agent platinums28,29 or combinations of carboplatin with 231 
gemcitabine in unselected TNBC30. The only other randomised trial conducted synchronous with our trial and 232 
designed to specifically investigate platinum in comparison with a standard of care in advanced TNBC included 233 
the substitution of cisplatin for paclitaxel given in a doublet with gemcitabine. In this study treatment was 234 
continued until disease progression, as is common practice with paclitaxel, and showed modestly greater activity 235 
for cisplatin31. A criticism of our study could be that patients did not receive treatment to progression but for 6 236 
cycles (and at investigator discretion maximum of 8 cycles), as was consistent with UK practice with docetaxel 237 
at the full licensed 100mg/m2 dose, as this is rarely tolerated for more than 6-8 cycles. This may explain shorter 238 
PFS compared to the study of Hu et al despite similar overall survival31, and may have underestimated the effect 239 
of carboplatin in those without a progression event during treatment and who might have continued event free 240 
for longer had treatment continued.  241 
 242 
In contrast to the unselected population, the pre-specified analyses of treatment effect in subgroups found 243 
evidence of clinically and statistically significant biomarker-treatment interactions. There is a strong association 244 
between BRCA1 mutation and basal-like cancer32 and sporadic basal-like breast cancer subtypes show high 245 
degrees of chromosomal genomic instability3. We hypothesised that if, as has been widely speculated, there was 246 
a shared profound BRCAness phenotype sporadic basal-like cancers might have very high platinum sensitivity. 247 
We found no evidence that basal-like biomarkers predicted higher response to platinum than docetaxel with the 248 
drugs showing similar activity. A significant treatment interaction was detected with the Prosigna PAM50 249 
identified subtypes; driven by significantly increased response to docetaxel relative to poor platinum response in 250 
non-basal forms of TNBC. This suggests absence of targetable BRCAness in non-basal TNBC and no evidence 251 
to change the standard of care from taxane to a platinum, which our data suggests is inferior in these subtypes. 252 
In contrast platinum is a reasonable option in those with basal TNBC particularly in those who fail to tolerate or 253 
have previously received a taxane. As the response rate is much less than that of BRCA1/2 mutation associated 254 
breast cancer, if there is a profound BRCAness phenotype that remains prevalent in metastatic basal-like breast 255 
cancer, beyond the context of BRCA1 or BRCA2 mutation, it appears  to lie within a yet to be identified 256 
subpopulation of this subtype.  257 
 258 
BRCA1/2 mutation testing is a clinically validated and widely available biomarker that predicted both greater 259 
response and PFS in favour of carboplatin over docetaxel demonstrating clinical utility for treatment selection in 260 
this setting. There was no evidence that mutation was associated with reduced activity of docetaxel compared to 261 
wildtype; docetaxel remains a valid and active, but inferior, treatment option in this setting. We did not find 262 
evidence of an overall survival advantage for carboplatin in BRCA1/2 mutation carriers, but interpretation is 263 
confounded by the crossover design as 56% received carboplatin at progression. The high levels of response 264 
seen for carboplatin were similar to those reported for the combination of carboplatin and paclitaxel in an 265 
essentially similar population in the reference comparator arm in the phase II BROCADE trial33, supporting the 266 
notion that carboplatin monotherapy is highly active in this patient group. We found approximately one third of 267 
BRCA1/2 carriers did not respond to platinum. Potential resistance mechanisms will be further explored in 268 
integrated whole genome and whole transcriptome sequencing analyses in primary tumour material but lack of 269 
extensive metastatic tumour from patients immediately prior to platinum treatment will limit sensitivity and 270 
ability to draw firm conclusions. 271 
 272 
In parallel we tested the hypothesis that epigenetic silencing of BRCA1 by DNA methylation would show a 273 
similar treatment interaction. Despite similar numbers in genetic and epigenetic BRCAness subgroups, patients 274 
with BRCA1 methylation or mRNA low had a higher response to docetaxel than carboplatin. Exploratory 275 
analyses seeking optimisation of cut-points and analysis of these epigenetic biomarkers as continuous variables 276 
failed to find any signal. In stark contrast to the interaction between BRCA1/2 mutation and carboplatin 277 
treatment effect we find no evidence to support a similar impact of epigenetic BRCAness with no interaction 278 
found between either BRCA1 methylation or BRCA1 mRNA low status and carboplatin treatment effect. This 279 
suggests important differences in the effects of genetic and epigenetic changes at the BRCA1 locus, at least in 280 
predicting therapy response in metastatic breast cancer exposed to prior adjuvant chemotherapy. These results 281 
are consistent with previous results from the non-randomised TBCRC 009 trial in metastatic TNBC28 where the 282 
few tumours with BRCA1 methylation showed no response to platinum despite evidence of chromosomal 283 
instability signatures. The majority of our patients had received adjuvant chemotherapies that cause DNA 284 
lesions that engage HR for repair. We measured BRCA1 methylation and mRNA in archived primary tumour 285 
specimens, whereas treatment effect was assessed in metastases. We speculate that in mutation carriers, a higher 286 
proportion retain an HR defect in metastatic disease than those with BRCA1 methylated tumours 287 
(Supplementary Figure S9). We suggest mutation creates a more resilient “hard” BRCAness whereas BRCA1 288 
methylation associated epigenetic BRCAness is more “soft” and plastic20. The methylation of BRCA1 may be 289 
both more heterogeneous and/or more revertible in subclinical metastases that, when subjected to selection 290 
pressure by DNA damaging adjuvant therapy, lose their HR defect and survive  subsequently developing as HR 291 
proficient and not selectively platinum sensitive metastases. Our hypothesis is supported by data from both pre-292 
clinical patient derived xenografts and primary breast tumours exposed to neo-adjuvant chemotherapy34. In 293 
ovarian cancers BRCA1 mutation but not methylation is associated with improved prognosis after platinum35,36 294 
and examination of pre- and post-platinum treatment biopsy pairs shows reversion of BRCA1 methylation in 295 
31% with continued presence of methylation being associated with PARP inhibitor response37. While defects in 296 
HR are known to be revertable mutational signatures would not be expected to disappear, as they are a 297 
permanent “scar” of prior, even if no longer active, HR defects. While our finding that the Myriad HRD assay 298 
did not have specific platinum response predictive performance in the advanced TNBC disease setting contrasts 299 
to reported association with platinum response in the neoadjuvant setting in TNBC26 these neoadjuvant studies 300 
do not have a comparator arm to allow a test of  interaction  between biomarker status and any specific 301 
treatment effect of platinum chemo as opposed to association with a relatively greater general chemotherapy 302 
responsiveness than HRD low status . Where this was examined in the randomised neoadjuvant context the 303 
Myriad HRD assay did not show specific predictive performance for platinum response in unplanned  304 
retrospective analyses with limited power38. Metastatic disease , exposed to prior adjuvant therapy is also a very 305 
different biological context. We hypothesise that adjuvant therapy drives reversal of the BRCA1 methylation 306 
“soft’ BRCAness34 HR defect, that we show like BRCA1 mutation leaves a high HRD score in the primary 307 
tumour (Figure S4),  erodes the positive predictive value of the HRD score for therapy response in metastasis 308 
while a low HRD Score will likely retain negative predictive value by excluding many tumours that have never 309 
had an HR defect whether “soft” or “hard”. Since our analysis, a novel HR deficiency mutational signature 310 
whole genome sequence analysis methodology called “HRDetect” has been described with preliminary evidence 311 
of potential application to FFPE clinical materials8. As HRDetect is also a cumulative historical measure of 312 
lifetime HR deficiency the positive predictive value of this method may also be eroded by the effects of reversal 313 
of epigenetic HR defects in treatment exposed metastatic disease and require integration with additional 314 
biomarkers of a tumour’s current HR status. Analyses of HRDetect and multiple additional mutational 315 
signatures, and their integration with transcriptional signatures of BRCAness and treatment response8,23,26,39,40 316 
are planned but require whole genome sequencing currently being piloted in TNT Trial FFPE material . These 317 
future analyses are beyond the scope of this manuscript. 318 
 319 
Previous randomised studies have not examined treatment effect in a priori defined subpopulations within 320 
advanced TNBC31. TNT highlights the heterogeneity in TNBC and need to investigate therapeutic effects with 321 
planned analyses of biological subgroups. We provide the first evidence of the clinical utility of BRCA1/2 322 
genotyping to inform therapy choice in metastatic familial breast cancer and TNBC. In early TNBC three recent 323 
trials have tested the role of the addition of platinum to anthracycline and taxane based neoadjuvant schedules, 324 
finding evidence of increased pathological tumour response41-43. These studies are underpowered for survival 325 
endpoints, but where reported, significant effects on disease free survival were only seen when the alkylating 326 
agent cyclophosphamide was omitted from the control arm backbone41. A non-significant trend was noted when 327 
a standard cyclophosphamide “backbone” control was used in the CALGB 40603 study42. The dose intense 328 
carboplatin regimen used in GeparSixto was recently compared with a sequential anthracycline and taxane and 329 
high dose cyclophosphamide-containing regimen with no differences found in the primary pathological response 330 
measures44. It would seem that the use of alkylating agents in early TNBC is important, especially for those that 331 
have higher stage disease with associated risk of recurrence requiring a maximally effective therapy, to reduce 332 
this risk and achieve optimal surgery. The balance of additional toxicity and paucity of appropriately powered 333 
survival analyses testing interaction with potential predictive biomarkers for platinum response suggest the need 334 
for more study before platinums are used routinely across all stages and biological subtypes of early TNBC. 335 
Data from our trial although conducted in advanced TNBC inform this landscape and raise important hypotheses 336 
for further testing in the early breast cancer setting. 337 
 338 
Many countries now perform inexpensive local BRCA1/2 germline testing. Our results support BRCA1/2 339 
germline testing to select patients for platinum chemotherapy for advanced disease. The OlympiAD trial 45 340 
recently reported comparison between the potent PARP inhibitor olaparib, known to trap PARP1 on DNA, in 341 
comparison to physicians choice of non-platinum standard of care chemotherapies in anthracycline and taxane 342 
exposed advanced gBRCA-BC. Other trials of potent PARP inhibitors are ongoing46. The PARP inhibitor 343 
olaparib is now approved in  advanced gBRCA-BC but this treatment may remain unaffordable to many health 344 
care systems and patients for many years. It remains unknown how potent PARP1-trapping inhibitors would 345 
compare with platinums in this setting but the TNT trial provides evidence that a widely available affordable 346 
off-patent biomarker has utility to select a population, enriched in the TNBCs prevalent in many developing 347 
countries47, who could benefit during this period from the biologically targeted use of highly active and 348 
inexpensive platinum chemotherapy agent rather than the current licensed breast cancer standard of care 349 
chemotherapies.  350 
 351 
Methods 352 
 353 
Study design 354 
Conducted in 74 hospitals throughout the UK TNT (NCT00532727) was a phase III, parallel group, open label 355 
randomised controlled trial with pre-planned biomarker subgroup analyses. Trial sponsorship, governance, 356 
randomisation procedures and balancing factors are described in the supplementary appendix.  357 
 358 
Patients 359 
Eligible patients had to be considered fit to receive either study drug and have measurable, confirmed advanced 360 
breast cancer unsuitable for local therapy with histologically confirmed ER, PgR, and HER2 negative primary 361 
invasive breast cancer with Allred/quick score <3 or H score <10 or locally determined ER and PgR negative, if 362 
other cut-offs used (e.g., 1%, 5% or 10%).  HER2 negative was defined as immunohistochemistry scoring 0 or 363 
1+ for HER2, or 2+ and non-amplified for HER2 gene by FISH or CISH. Patients could be ER and HER2 364 
negative and, PgR negative/unknown, or any ER, PgR and HER2 status if known to have BRCA1 or BRCA2 365 
germline mutation and otherwise eligible (full eligibility criteria in supplementary appendix). Although patients 366 
with TNBC hypothesised to have BRCAness phenotypes were the primary interest, patients with unselected 367 
TNBC as well as those with BRCA1 or BRCA2 germline mutations were recruited to allow interaction testing of 368 
biomarker positive and negative populations in relation to response to each of these mechanistically distinct 369 
agents. Patients provided written informed consent.  370 
 371 
 372 
Procedures 373 
Patients were allocated (1:1 ratio) between six cycles of carboplatin (AUC 6), day 1 3-weekly, and six cycles of 374 
docetaxel (100mg/m2), day 1 3-weekly (see supplementary appendix section 3.1 for details of allocation 375 
procedures including minimisation balancing factors used). For patients responding to and tolerating treatment 376 
well, a further two cycles could be given subject to local policy. Further details of chemotherapy and supportive 377 
medicines are described in the supplementary appendix. Patients were offered six cycles of the alternative 378 
(“crossover”) treatment upon progression or where allocated treatment was discontinued due to toxicity (“pre-379 
progression crossover”). Subsequent management was at clinician discretion.  380 
 381 
Tumour assessment by CT scan was performed after three and six cycles (or at treatment discontinuation if 382 
earlier) and three-monthly thereafter until disease progression. Response was assessed as best response by 383 
RECIST.  384 
 385 
Sample analyses 386 
For consenting patients, one blood sample and archival primary invasive carcinoma, lymph nodes and any 387 
recurrent tumour specimens, or a research biopsy from a metastatic site, were collected. There was no 388 
requirement for a recurrent specimen to be provided. DNA was extracted using standard methodology. Central 389 
review of ER, PgR and HER status was performed at KCL (further details in supplementary appendix). 390 
 391 
Germline BRCA1 and BRCA2 mutation analysis was conducted and status for subgroup analysis was centrally 392 
determined at The Institute of Cancer Research. Genomic DNA from blood white cell preparations was analysed 393 
for BRCA1 and BRCA2 for intragenic mutations and exon deletions and duplications throughout the coding 394 
sequence, and intron-exon boundaries was completed in all cases. This was either performed by Sanger 395 
sequencing together with multiplex ligation-dependent probe amplification (MLPA) or by next-generation 396 
sequencing using the Illumina TruSight Cancer Panel v1. All intragenic mutations were confirmed by separate 397 
bi-directional Sanger sequencing. All exon deletions or duplications were confirmed by MLPA. The mutation 398 
nomenclature was in accordance with clinical convention with numbering starting at the first A of the ATG 399 
initiation site, using BRCA1  LRG_292_t1 and BRCA2 LRG_293_t1. 400 
 401 
The DNA methylation status of the regulatory region of BRCA1 was determined using bisulfite sequencing and 402 
BRCA1 mRNA expression level from total-RNA-sequencing from archival primary carcinoma (see 403 
supplementary appendix Figure S3 and Supplementary Table S5). 404 
 405 
The Myriad HRD test includes three DNA-based measures of homologous recombination deficiency including: 406 
whole genome tumour loss of heterozygosity profiles (LOH), telomeric allelic imbalance (TAI) and large-scale 407 
state transitions (LST)22-24. All three scores are highly correlated with defects in BRCA1/2 and predict response 408 
to platinum-containing neoadjuvant chemotherapy in patients with TNBC trials without standard of care control 409 
arms26. The HRD score is calculated as the sum of the three individual scores, and a previously validated 410 
threshold of 42 was utilized in these analyses 26. As part of the HRD assay, the sequencing data are used to call 411 
BRCA1/2 mutations in the tumour, either germline or somatic.  The supplementary appendix includes 412 
description of HRD assay on TNT trial samples. 413 
 414 
Primary cancers were classified into basal-like subtypes by several classifiers including an IHC panel7, and 415 
Prosigna48(further details in supplementary appendix). Integration of transcriptional and whole genome 416 
chromosomal instability, rearrangement and mutational signatures that have been associated with BRCA1 or 417 
BRCA2 mutation and BRCA1 methylation and may specifically interact with carboplatin response 8,22-26,39,40 418 
were protocol pre-specified as a priori sub-groups analyses are incomplete and will be reported elsewhere.  419 
 420 
Outcomes 421 
The primary endpoint was objective tumour response rate (complete or partial). The version of RECIST 422 
reporting criteria used for tumour assessment was documented and, where possible, cases assessed using 423 
RECIST version 1.0 were subsequently reassessed locally according to RECIST version 1.1. An independent 424 
Response Evaluation Committee at study completion reviewed reported responses centrally (local assessment 425 
was used for primary analysis).  426 
 427 
Secondary endpoints included progression free survival (PFS), overall survival (OS), response to crossover 428 
treatment (as per primary endpoint), tolerability and safety.  429 
 430 
Adverse events were assessed throughout treatment; graded according to National Cancer Institute Common 431 
Toxicity Criteria (version 3·0) and coded according to the Medical Dictionary for Regulatory Activities 432 
(MedDRA version 14·0) with central clinical review (by the Chief Investigator) at study completion. 433 
 434 
Statistical analyses 435 
Evidence to inform sample size calculations was scarce; however ECOG 210049 suggested a 20-30% response 436 
rate for single agent taxane. TNT was designed on the premise of demonstrating superiority of carboplatin with 437 
a 15% improvement in response rates designated as clinically important. Assuming 90% power and type I error 438 
α=0·05 (two-sided), a sample size of at least 370 patients was required. The protocol recognised a priori that 439 
equivalence of response, accompanied by reduced toxicity with carboplatin, would also impact clinical practice. 440 
 441 
Response rates were compared using 2-sided Fisher’s exact tests and logistic regression (see supplementary 442 
appendix section 4.10 for further details regarding analysis of subgroups).  Survival endpoints were displayed 443 
using Kaplan Meier plots and survival analysis modelling utilised restricted mean survival methodology50 given 444 
that the proportionality of hazards assumption required for Cox survival analysis did not hold.  445 
 446 
Principal efficacy endpoints were analysed according to intention to treat (ITT) including all 376 patients 447 
randomised and according to pre-planned biomarker subgroups (Table S1); additional analysis groups and 448 
associated analysis methods are detailed in the supplementary appendix. Analyses are based on a database 449 
snapshot taken on 7 March 2016 and performed using STATA 13.  450 
 451 
Life Sciences Reporting Summary 452 
Further information on experimental design is available in the Life Sciences Reporting Summary. 453 
 454 
 455 
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Figure 1. Consort diagram 672 
Flow of participants in the trial. 673 
 674 
Figure 2. Response rates (overall and BRCA subgroups) 675 
Absolute differences between treatment groups within biomarker subgroups are presented; p-values for the 676 
differences are calculated using a 2-sided Fisher’s exact test. P-values for interactions are based on a logistic 677 
regression model of response with terms for biomarker status, treatment group and interaction. 678 
Figure 3. Progression-free survival (overall and BRCA subgroups) 679 
Data presented is the difference in PFS restricted mean (95% CI). A negative value indicates a better response to 680 
docetaxel, positive values indicate better response to carboplatin. P-values are calculated using a 2-sided t-test 681 
comparing the mean survival between treatments (within biomarker groups as appropriate). C=Carboplatin; 682 
D=Docetaxel. 683 
Figure 4. Response rates (HRD subgroups) 684 
Absolute differences between treatment groups within HRD subgroups are presented; p-values for the 685 
differences are calculated using a 2-sided Fisher’s exact test. P-values for interactions are based on a logistic 686 
regression model of response with terms for biomarker status, treatment group and interaction. 687 
Figure 5. Response rates (basal-like subgroups)  688 
Absolute differences between treatment groups within basal subgroups are presented; p-values for the 689 
differences are calculated using a 2-sided Fisher’s exact test. P-values for interactions are based on a logistic 690 
regression model of response with terms for biomarker status, treatment group and interaction. 691 
Figure 6. PFS (basal-like subgroups) 692 
Data presented is the difference in PFS restricted mean within subgroups (95% CI). A negative value indicates a 693 
better response to docetaxel, positive values indicate better response to carboplatin. P-values are calculated 694 
using a 2-sided t-test comparing the mean survival between treatments within biomarker groups. C=Carboplatin; 695 
D=Docetaxel. 696 
 697 
Data availability 698 
Gene expression profiling data of the 50 genes used for Prosigna algorithm is available at: 699 
https://doi.org/10.5281/zenodo.1172633. 700 
Other dichotomised biological data used for subgroup analyses is available in supplementary dataset 1. 701 
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